Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 16

1180P - Treatment patterns and progression-free survival in MET exon 14 (METex14) skipping advanced non-small cell lung cancer (aNSCLC) in real-world clinical practice

Date

10 Sep 2022

Session

Poster session 16

Topics

Pathology/Molecular Biology;  Targeted Therapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Cheryl Ho

Citation

Annals of Oncology (2022) 33 (suppl_7): S448-S554. 10.1016/annonc/annonc1064

Authors

C. Ho1, S. Wong2, A. Hatswell3, R. Slater3, H. Vioix4, C. Chouaid5

Author affiliations

  • 1 Department Of Medical Oncology, BC Cancer, Vancouver, Canada; University of British Columbia, BC V6T 1Z4 - Vancouver/CA
  • 2 Department Of Medical Oncology, BC Cancer, Vancouver, Canada; University of British Columbia, Vancouver/CA
  • 3 -, Delta Hat, Nottingham/GB
  • 4 Global Evidence And Value Development, Merck Healthcare KGaA, Darmstadt/DE
  • 5 Service De Pneumologie, CHI Créteil, Créteil, France; Institut Mondor de Recherche Biomédicale, U955 Inserm-Université Paris Est Créteil, Créteil/FR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1180P

Background

METex14 skipping is present in 3–4% of patients with aNSCLC. Several MET-specific targeted therapies have recently been licensed, however the lack of randomized studies make inferences on comparative effectiveness complex. We evaluated treatment patterns and progression-free survival (PFS) using real-world data collected prior to the regulatory approvals of MET-specific tyrosine kinase inhibitors (TKIs).

Methods

Five real-world datasets of patients with METex14 skipping aNSCLC were pooled (data collected: 2011–2020); published data from a Western Canadian province, three international non-interventional studies, and French routine practice data. Patient records were included using a common data model with aligned definitions, and the best available definition of PFS was used.

Results

The analysis included 248 patients (54% female, 53% with smoking history), with a median age of 72 years. Of the 516 lines of therapy included, the majority could be categorized as chemotherapies (204), MET inhibitors (137; over 90% were crizotinib), or immunotherapy (119; mostly pembrolizumab and nivolumab). In general, patients received chemotherapy as a first-line therapy (118/220 identifiable lines). Across all treatment classes and treatment lines, median PFS (95% CI) were short; 5.0 (4.5, 7.5) vs 3.9 months (3.4, 5.2) for treatment-naïve vs previously treated patients receiving chemotherapy; 8.0 (4.0, 11.1) vs 7.0 months (5.6, 9.9) for MET inhibitors; and 3.6 (2.0, 10.2) vs 3.3 months (2.5, 5.7) for immunotherapies.

Conclusions

This international real-world analysis – conducted prior to the approval of MET-specific TKI therapies – showed that outcomes for patients with METex14 skipping aNSCLC were poor across all available therapy classes and treatment lines.

Clinical trial identification

Editorial acknowledgement

Medical writing assistance (funded by Merck Healthcare KGaA, Darmstadt, Germany) was provided by Syneos Health, London, UK.

Legal entity responsible for the study

Merck Healthcare KGaA, Darmstadt, Germany.

Funding

Merck Healthcare KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945).

Disclosure

C. Ho: Financial Interests, Personal, Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, BMS, Eisai, EMD Serono, Janssen, Merck, Novartis, Pfizer, Roche, Takeda; Financial Interests, Institutional, Research Grant: AstraZeneca, EMD Serono, Roche; Non-Financial Interests, Principal Investigator: Roche, AstraZeneca, EMD Serono. A. Hatswell, R. Slater: Financial Interests, Personal, Full or part-time Employment: Delta Hat. H. Vioix: Financial Interests, Personal, Full or part-time Employment: Merck Healthcare KGaA, Darmstadt, Germany. C. Chouaid: Financial Interests, Personal, Advisory Board: AZ, BI, GSK, Roche, Sanofi-Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen; Financial Interests, Institutional, Funding: AZ, BI, GSK, Roche, Sanofi-Aventis, BMS, MSD, Lilly, Novartis, Pfizer, Takeda, Bayer, Janssen and Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.